Corpus overview


MeSH Disease

Human Phenotype


There are no transmission terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page

    Cirrhosis HP Cirrhosis MESHD and COVID-19: a fatal case of viral peritonitis MESHD peritonitis HP and disseminated infection MESHD

    Authors: Victor Cabelho Passarelli; Ana Helena Perosa; Luciano Luna; Danielle Dias Conte; Oliver A. Nascimento; Jaquelina Ota-Arakaki; Nancy Bellei

    doi:10.1101/2020.06.25.20139998 Date: 2020-06-29 Source: medRxiv

    Pathogenesis and clinical presentation of Coronavirus Disease-19 outside the respiratory tract remain to be understood, especially in the immunocompromised. We report an unique case of cirrhosis HP cirrhosis MESHD decompensation with ascites HP ascites MESHD and unprecedented evidence of SARS Coronavirus-2 peritonitis MESHD peritonitis HP and disseminated infection, demonstrated by viral RNA detection in peritoneal fluid, as well as in blood SERO serum SERO, nasopharyngeal and stool specimens.

    Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

    Authors: Wayne Vuong; Muhammad Bashir Khan; Conrad Fischer; Elena Arutyunova; Tess Lamer; Justin Shields; Holly A Saffran; Ryan T McKay; Marco J van Belkum; Michael Joyce; Howard S Young; D. Lorne Tyrrell; John C Vederas; M Joanne Lemieux

    doi:10.1101/2020.05.03.073080 Date: 2020-05-04 Source: bioRxiv

    The COVID-19 pandemic, attributed to the SARS-CoV-2 coronavirus infection MESHD, resulted in millions infected MESHD worldwide and an immediate need for antiviral treatments. The main protease (Mpro) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide and subsequent viral replication. Feline infectious peritonitis MESHD peritonitis HP, a fatal infection MESHD in cats caused by a coronavirus, was successfully treated previously with a dipeptide-based protease inhibitor. Here we show this drug, GC376, and its analog GC373, are effective inhibitors of the Mpro from both SARS-CoV and SARS-CoV-2 MESHD with IC50 values in the nanomolar range. Crystal structures of the SARS-CoV MESHD and SARS-CoV-2 Mpro with these inhibitors have a covalent modification of the nucleophilic Cys145. NMR analysis reveals that inhibition proceeds via reversible formation of a hemithioacetal. GC373 and GC376 are potent inhibitors of SARS-CoV-2 in cell culture, with EC50 values near one micromolar and little to no toxicity MESHD. These protease inhibitors are soluble, non-toxic, and bind reversibly. They are strong drug candidates for the treatment of human coronavirus infections MESHD because they have already been successful in animals (cats). The work here lays the framework for their use in human trials for the treatment of COVID-19.

    SARS-CoV-2 neutralizing serum SERO antibodies SERO in cats: a serological investigation

    Authors: Meilin Jin

    doi:10.1101/2020.04.01.021196 Date: 2020-04-03 Source: bioRxiv

    Coronavirus disease MESHD 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) was first reported in Wuhan, China, and rapidly spread worldwide. Previous studies suggested cat could be a potential susceptible animal of SARS-CoV-2. Here, we investigated the infection of SARS-CoV-2 MESHD in cats by detecting specific serum SERO antibodies SERO. A cohort of serum samples SERO were collected from cats in Wuhan, including 102 sampled after COVID-19 outbreak, and 39 prior to the outbreak. 15 of 102 (14.7%) cat sera collected after the outbreak were positive for the receptor binding domain (RBD) of SARS-CoV-2 by indirect enzyme linked immunosorbent assay SERO ( ELISA SERO). Among the positive samples, 11 had SARS-CoV-2 neutralizing antibodies SERO with a titer ranging from 1/20 to 1/1080. No serological cross-reactivity was detected between the SARS-CoV-2 and type I or II feline infectious peritonitis virus MESHD peritonitis HP virus (FIPV). Our data demonstrates that SARS-CoV-2 has infected cat population in Wuhan during the outbreak.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.